Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Bristol acquires fibrotic disease company Amira for $325mm up front

Executive Summary

Marking its first foray into the fibrotic disease area, Bristol-Myers Squibb Co. is acquiring private Amira Pharmaceuticals Inc. (developing small molecules for disorders caused by inflammation) for $325mm up front and up to $150mm in earn-outs, in three increments of $50mm each. (One of the milestone payments is expected sometime this year.)
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Full Acquisition
    • Includes Earnout
    • Payment Includes Cash

Related Companies